March 23, 2018 / 6:06 AM / 9 months ago

BRIEF-Innate Pharma Expands mCRC Cohort In Phase I Trial Evaluating Monalizumab With Imfinzi

March 23 (Reuters) - Innate Pharma Sa:

* REG-INNATE PHARMA : EXPANSION OF MCRC COHORT IN PHASE I TRIAL EVALUATING MONALIZUMAB WITH IMFINZI

* PRIMARY OBJECTIVE OF NEW STUDY ARMS WILL BE SAFETY

* ‍DOSE-ESCALATING PART OF STUDY HAS BEEN COMPLETED, WHILE EXPANSION COHORTS IN SELECTED ADVANCED SOLID TUMORS ARE ONGOING​

* OVERALL RESPONSE RATE AND DURATION OF RESPONSE, AMONGST OTHERS, AS SECONDARY OUTCOME MEASURES

* FIRST CLINICAL DATA READ-OUTS FROM PHASE I STUDY AND INITIAL EXPANSION COHORT PROGRAM DURING 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below